FDA Approves Anti-Clotting Drug Savaysa
The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
FDA Delays Blood Thinner Eliquis Again
United States Food and Drug Administration officials today delayed approval of Eliquis ( apixaban ) to prevent stroke or systemic embolism in patients with a common heart arrhythmia for the second time.
Risk High During Temporary Anticoagulant Halts
Patients with certain types of atrial fibrillation, a common heart arrhythmia, are at a high risk of stroke and blood clots if they temporarily stop their blood thinning medication before surgery or permanently because of side effects.
Apixaban Fails to Reduce Blood Clots
An experimental drug designed to aid severely ill patients after hospitalization is not more effective than standard treatments for reducing the risk of blood clots, a study has confirmed.